Skeletal-related events due to bone metastases from differentiated thyroid cancer.
暂无分享,去创建一个
[1] G. Hortobagyi,et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases , 2000, Cancer.
[2] M. Hameed,et al. Atypical subtrochanteric femoral fractures in patients with skeletal malignant involvement treated with intravenous bisphosphonates. , 2011, The Journal of bone and joint surgery. American volume.
[3] Y. Fujiwara,et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] A. Howell,et al. Long‐term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma , 2003, Cancer.
[5] Shinichiro,et al. Carcinoma , 1906, The Hospital.
[6] S. Larson,et al. Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty-six patients. , 2000, Thyroid : official journal of the American Thyroid Association.
[7] R. Bell,et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer , 2004, Pain.
[8] M. Carducci,et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study , 2011, The Lancet.
[9] Y. Ohashi,et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] C. Shapiro,et al. Task Force Report : Bone Health in Cancer Care , 2013 .
[11] A. Abbruzzese,et al. Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer , 2001, British Journal of Cancer.
[12] R. Coleman. Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity , 2006, Clinical Cancer Research.
[13] S. Larson,et al. The Effect of Posttherapy 131I SPECT/CT on Risk Classification and Management of Patients with Differentiated Thyroid Cancer , 2010, The Journal of Nuclear Medicine.
[14] J. Manabe,et al. Zoledronic acid in the treatment of bone metastases from differentiated thyroid carcinoma. , 2011, Thyroid : official journal of the American Thyroid Association.
[15] E. Baudin,et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. , 2006, The Journal of clinical endocrinology and metabolism.
[16] M. Krzakowski,et al. Long‐term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors , 2004, Cancer.
[17] R. Zarnegar,et al. Bone metastases from differentiated thyroid carcinoma. , 2008, Endocrine-related cancer.
[18] M. Lichinitser,et al. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. , 2004, European journal of cancer.
[19] R. Theriault,et al. Executive Summary of the Clinical Practice Guideline Update on the Role of Bone-Modifying Agents in Metastatic Breast Cancer , 2013 .
[20] R. Coleman. Bisphosphonates: clinical experience. , 2004, The oncologist.